

Technology Advisory Committee C Interests Register

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs only have failed - partial review of TA375 [ID2710]

Publication Date: 14 July 2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	TAC Committee Member	Financial	Michael has recently been co-ordinating a training programme for Roche in Real World Evidence, but this has not involved specific consideration of any Roche medicines.	N/A	15.02.2021	N/A	It was agreed that this declaration would not prevent Michael from participating in discussions on this appraisal.
Dr Prithwiraj Das	TAC Committee Member	Non-financial	Prithwiraj is employed by AstraZeneca as Head of Market Access, Respiratory and Immunology.	N/A	03.03.2021	N/A	It was agreed that this declaration would not prevent Prithwiraj from participating in discussions on this appraisal.
Dr Richard Nicholas	TAC Committee Member	Financial	Richard has attended paid advisory boards for Novartis, Biogen, and	N/A	18.02.2021	N/A	It was agreed that this declaration would not prevent

			Roche in an unrelated area.				Richard from participating in discussions on this appraisal.
Professor Paul Tappenden	TAC Committee Member	Non-financial	Paul is employed by SchARR (the Assessment Group for this appraisal). Paul confirmed he has not been involved in the production or peer review of the ERG report.	N/A	15.02.2021	N/A	It was agreed that this declaration would not prevent Paul from participating in discussions on this appraisal.
Ailsa Bosworth	Patient expert	Financial	NRAS has received educational grants in the last 12 months from some of the companies involved in this MTA.	N/A	01.10.2020	N/A	It was agreed that this declaration would not prevent Ailsa from providing expert advice to the committee.
Dr Frank McKenna	Clinical expert	Financial	Frank was in receipt of an honorarium from Biogen in December 2019 for giving a lecture to non-medical prescribers on NICE guidelines and guidance in Rheumatology and Gastroenterology. The meeting was funded by Biogen.	N/A	16.09.2020	N/A	It was agreed that this declaration would not prevent Frank from providing expert advice to the committee.
Professor Peter Taylor	Clinical expert	Financial	Peter's PCT has received consultation fees from	N/A	15.09.2020	N/A	It was agreed that this declaration

			AbbVie, BMS, Biogen, Janssen, Pfizer, Roche, Fresenius Kabi and UCB. Peter is Chief Medical Adviser to NRAS.				would not prevent Peter from providing expert advice to the committee.
--	--	--	--	--	--	--	--